Latest News by Industry
WATERTOWN, Mass.--(BUSINESS WIRE)--Sep 3, 2024--
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will participate in three investor conferences being webcast in September:
A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcasts will be available following the presentation and will be archived for at least 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
View source version on businesswire.com:https://www.businesswire.com/news/home/20240903775265/en/
CONTACT: Media and Investors:
Jennifer Viera
617-744-3848
jviera@enanta.com
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: FDA HEALTH COVID-19 CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Enanta Pharmaceuticals, Inc.
Copyright Business Wire 2024.
PUB: 09/03/2024 07:00 AM/DISC: 09/03/2024 07:01 AM
http://www.businesswire.com/news/home/20240903775265/en